




FIG. 1




FIG. 2

3/31




FIG. 3




FIG. 4

5/31




FIG. 5

ATO20
2021+ EARLY PASSAGE MS5hDLL4H




FIG. 5
(CONT.-1)




FIG. 6

ATO 20 AND 21 T CELL SORT ON ARIA

OPTIMIZER MEDIUM;
rhIL-2, 300 U/ml;
ANTICD3/28 BEADS, 10:1 ~ 2:1 BEAD : CELL RATIO

96W ROUND BOTTOM TC PLATE
HALF/COMPLETE MEDIUM CHANGE AND SPLIT AS NECESSARY




FIG. 6
(CONT.-1)

FIG. 7




PLATE-BOUND OKT3 STIMULATION (14H), CELLS PRE-GATED ON CD3+

10/31




FIG. 7
(CONT.-1)

FIG. 8	FIG. 8 (CONT.-2)	FIG. 8 (CONT.-4)
FIG. 8 (CONT.-1)	FIG. 8 (CONT.-3)	FIG. 8 (CONT.-5)





FIG. 8

12/31






FIG. 8	FIG. 8 (CONT-2)	FIG. 8 (CONT-4)
FIG. 8 (CONT-1)	FIG. 8 (CONT-3)	FIG. 8 (CONT-5)




FIG. 8
(CONT.-3)





FIG. 8
(CONT.-4)

FIG. 8	FIG. 8 (CONT-2)	FIG. 8 (CONT-4)
FIG. 8 (CONT-1)	FIG. 8 (CONT-3)	FIG. 8 (CONT-5)






FIG. 9

18/31





FIG. 9
(CONT.-1)

19/31



MSD TEST OF ATO 20/21 DERIVED T CELL OKT3 STIMULATION (14h)

FIG. 10





FIG. 11

21/31

**FIG. 12**

22/31





FIG. 12
(CONT.-1)

23/31

**FIG. 13**

24/31




FIG. 14




FIG. 15




FIG. 16A

27/31




FIG. 16A
(CONT.-1)




FIG. 16B




FIG. 16B
(CONT.-1)




FIG. 16C




FIG. 16C
(CONT.-1)